logo
Twitter
Discord
Email
logo
Cidara Therapeutics, Inc.

Cidara Therapeutics, Inc.

NASDAQ•CDTX
CEO: Dr. Jeffrey L. Stein Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2015-04-15
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
Contact Information
6310 Nancy Ridge Drive, Suite 101, San Diego, CA, 92121, United States
858-752-6170
www.cidara.com
Market Cap
$5.61B
P/E (TTM)
-18.6
38.2
Dividend Yield
--
52W High
$221.42
52W Low
$15.22
52W Range
100%
Rank59Top 87.6%
2.2
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$3.10+30.25%
4-Quarter Trend

FCF

-$40.62M+10.36%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Strong Liquidity Position Total assets reached $518.65M, up 142% from $214.80M, funded by June 2025 public offering proceeds.
CD388 Phase 2b Efficacy CD388 450mg dose showed 76.1% prevention efficacy in NAVIGATE study; Phase 3 ANCHOR trial initiated.
EPS Loss Narrows Diluted net loss per share improved to $(7.00) from $(22.53) due to significant common share increase post-financing.
Zero Collaboration Revenue Nine-month collaboration revenue dropped to zero USD following Janssen agreement termination effective April 2024.

Risk Factors

Additional Funding Required Continued operations beyond Phase 3 depend on obtaining additional capital on acceptable terms, facing market volatility risks.
Clinical Trial Execution Risk Delays in CD388 Phase 3 ANCHOR enrollment or failure to demonstrate safety/efficacy halt commercialization prospects.
Manufacturing Supply Chain Reliance on third-party manufacturers, including WuXi XDC in China, creates supply chain disruption and tariff risks.
Stock Dilution Potential Significant outstanding preferred stock, warrants, and options pose material dilution risk upon future conversion events.

Outlook

Advance CD388 Phase 3 Focus remains on enrolling 6,000 participants in global ANCHOR Phase 3 trial, targeting completion by December 2025.
Utilize BARDA Funding BARDA contract provides estimated $58.1M base funding over 24 months to support CD388 manufacturing onshoring.
Cash Funds Phase 3 Current cash, equivalents, and investments of $476.5M expected to fund operations through Phase 3 completion.
Pipeline Development Focus Prioritize CD388 development; CBO421 oncology candidate remains early stage with no immediate clinical trials planned.

Peer Comparison

Revenue (TTM)

Apellis Pharmaceuticals, Inc.APLS
$1.02B
+42.1%
Legend Biotech CorporationLEGN
$908.96M
+74.7%
Zai Lab LimitedZLAB
$441.63M
+24.1%

Gross Margin (Latest Quarter)

Apellis Pharmaceuticals, Inc.APLS
94.7%
+11.7pp
Tarsus Pharmaceuticals, Inc.TARS
79.3%
-14.0pp
Zai Lab LimitedZLAB
59.6%
-4.3pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
CDTX$5.61B-18.6-60.1%0.4%
SRRK$4.59B-14.5-122.0%26.7%
XENE$3.09B-10.3-46.2%1.4%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 5, 2026
|
EPS:-$1.36
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 6, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-3.10+30.3%
    N/A

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 7, 2025|
    Revenue: $0.00-100.0%
    |
    EPS: $-1.65-91.6%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 8, 2025|
    Revenue: $0.00-100.0%
    |
    EPS: $-1.66-27.2%
    N/A

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 6, 2025|
    Revenue: $1.28M-94.5%
    |
    EPS: $-26.75-409.5%
    Miss

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 7, 2024|
    Revenue: $0.00-100.0%
    |
    EPS: $-2.38+31.5%
    N/A

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 13, 2024|
    Revenue: $302.00K-96.0%
    |
    EPS: $-19.59+599.6%
    Miss

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 15, 2024|
    Revenue: $8.46M-67.6%
    |
    EPS: $-2.28-396.1%
    Meet

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Apr 22, 2024|
    Revenue: $63.91M-0.6%
    |
    EPS: $-5.25+45.4%
    Miss